Divalproex Sodium Tablet, Delayed Release
Product Images NDC 70518-3683

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 70518-3683). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
Label for Divalproex Sodium 125 mg delayed-release oral tablets in a quantity of 30. The label indicates prescription only, repackaged by RemedyRepack Inc., with manufacturing by Rising Pharma, Inc., Allendale, NJ. Storage instructions and a barcode with a QR code are present on the label.*
FDA Label Image

Figure 1 (Divalproex Fig1)

Figure 1 (Divalproex Fig1)
A vertical bar chart comparing response percentages between placebo (PBO) and divalproex sodium delayed-release tablets (DVPX) across two studies. Study 1 (YMRS) shows 26% for PBO and 60% for DVPX, while Study 2 (MRS) shows 29% for PBO and 58% for DVPX. Statistical significance is noted with p < 0.05.*
FDA Label Image

Figure 2 (Divalproex Fig2)

Figure 2 (Divalproex Fig2)
A line graph illustrating the percentage reduction in CPS rate comparing Divalproex Sodium Delayed-Release Tablets to a placebo across patient percentages. The y-axis shows percent reduction in CPS rate with an upward arrow indicating improvement and a downward arrow indicating worsening. The x-axis represents the percentage of patients. The graph shows distinct curves for Divalproex Sodium and placebo, indicating their comparative effects.*
FDA Label Image

Figure 3 (Divalproex Fig3)

Figure 3 (Divalproex Fig3)
A line graph labeled Figure 3 showing the percentage reduction in CRS rate on the vertical axis and percentage of patients on the horizontal axis. Two lines compare high dose and low dose groups, with the graph indicating improvement and worsening directions for the CRS rate reduction.*
FDA Label Image

Figure 4 (Divalproex Fig4)

Figure 4 (Divalproex Fig4)
A bar chart titled 'Figure 4 Mean 4-week Migraine Rates' comparing migraine rates over 4 weeks between placebo and divalproex sodium delayed-release tablets in two separate studies. The vertical axis measures migraine rates from 0 to 6. Study 1 shows lower migraine rates for divalproex sodium versus placebo, and Study 2 similarly shows reduced migraine rates with divalproex sodium compared to placebo. Footnotes detail dosing information for both studies.*
FDA Label Image

Chemical Structure (Divalproex Str)

Chemical Structure (Divalproex Str)
Chemical structure diagram of the active ingredient Divalproex Sodium, showing its molecular components including hydrocarbon chains, carboxylate groups, and sodium ion in a polymeric form.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.